Volunteer Login Study Team Login


Lay Description

Creatine is one of the most studied supplements with research demonstrating its efficacy in augmenting training adaptations such as improved strength and physical function in a variety of healthy and clinical populations. Given the additive effects of creatine and exercise improving muscle performance and lean body mass, it is not surprising that creatine is being explored as a cancer therapeutic to improve survivorship. However, the paucity of research in this area stems from the lack of awareness of the potential role of creatine supplementation in cancer survivors. Therefore, the purpose of this project is to test the hypothesis that creatine will accelerate adaptations associated with exercise in cancer survivors that are engaged in the Thrivewell Exercise Program.


  • Cancers and Other Neoplasms
  • Cancer Survivors
IRB Number
NCT Number
Open to Enrollment


Eligible Ages
18 - 75
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Age 18-75 years of age
  • Recent (within 6 months) completion of chemotherapy
  • Willing to attend 3 clinic based exercise sessions per week
  • Able to take oral medications

Participant is willing and able to provide consent to participating in the study

Exclusion Criteria

  • Physical indications where performing exercise may be limited and/or contraindicated poorly-controlled hypertension (blood pressure > 160/95mmHg)
  • Current tobacco use (within 6 months)
  • Anabolic steroids
  • Pitting edema
  • Currently undergoing medical treatment for cancer (i.e. currently undergoing hormone therapy, chemotherapy or radiation therapy).
  • History of moderate-severe heart disease (New York Heart Classification greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of stairs or less; abnormal breath sounds on auscultation).
  • Abnormal lab values for serum creatinine
  • Currently taking creatine supplements

Study Design

Study Contact

Regulatory Point of Contact
Amber Gallegos
(210) 606-2437

Regulatory Point of Contact
Darpan Patel
(210) 567-0362

Local Recruitment Point of Contact
Amber Gallegos
(210) 606-2437

Overall Recruitment Point of Contact
Angela Gonzalez


Principal Investigator
Darpan Patel